Literature DB >> 27865879

Arachidonic acid has protective effects on oxygen-glucose deprived astrocytes mediated through enhancement of potassium channel TREK-1 activity.

Li Lu1, Guangru Zhang2, Chunli Song3, Xuexi Wang4, Weina Qian5, Zhuanling Wang6, Yanan Liu1, Sheng Gong6, Shuning Zhou6.   

Abstract

Polyunsaturated fatty acids (PUFAs) have neuroprotective effects against ischemic brain diseases. The newly discovered potassium channel "TREK-1" is a promising target for therapies against neurodegeneration. Arachidonic acid (AA) is an n-6 PUFA, as well as a potent TREK-1 activator. We previously showed that TREK-1 is expressed at high levels in astrocytes. However, the effect of AA on astrocytes in ischemia remains unknown. Here, we assessed the effects of 3-30μM AA on astrocyte apoptosis, glutamate uptake, and expression of the astrocytic glutamate transporter 1 (GLT-1) and TREK-1 under different conditions. Under normal conditions, 3-30μM AA showed no effect on astrocytic apoptosis or TREK-1 expression, whereas glutamate uptake decreased significantly and its change paralleled the decreased expression of GLT-1. When astrocytes were subjected to 4h of oxygen-glucose deprivation (OGD), 10μM AA markedly alleviated OGD-induced cell death, recovering from 63.50±1.90% to 82.96±4.63% of the control value. AA also rescued the decreased glutamate uptake and increased mRNA, as well as protein levels of GLT-1 and TREK-1. Our results provide new evidence of a protective effect of AA on astrocytes under OGD conditions, suggesting that a low concentration of AA may protect against brain ischemic diseases. Copyright Â
© 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Arachidonic acid; Astrocytes; Oxygen-glucose deprivation; TREK-1

Mesh:

Substances:

Year:  2016        PMID: 27865879     DOI: 10.1016/j.neulet.2016.11.034

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Activation of the TREK-1 Potassium Channel Improved Cognitive Deficits in a Mouse Model of Alzheimer's Disease by Modulating Glutamate Metabolism.

Authors:  Fang Li; Shu-Ning Zhou; Xin Zeng; Zhen Li; Rui Yang; Xue-Xi Wang; Bin Meng; Wei-Lin Pei; Li Lu
Journal:  Mol Neurobiol       Date:  2022-06-09       Impact factor: 5.682

2.  Effects of sevoflurane on rats with ischemic brain injury and the role of the TREK-1 channel.

Authors:  Lixiao Pan; Fengyun Yang; Caixia Lu; Changxin Jia; Qing Wang; Kexue Zeng
Journal:  Exp Ther Med       Date:  2017-08-08       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.